Viking Therapeutics Surges as Obesity Drug Hopes Rise

Viking Therapeutics ( (VKTX) ) has risen by 7.24%. Read on to learn why.

Viking Therapeutics’ share price climbed 7.24% over the past week as investors reacted positively to an ambitious obesity-drug strategy outlined on its latest earnings call. The company reported strong Phase II results for its lead candidate VK2735, with the injectable version delivering up to 14.7% weight loss over 13 weeks and the oral pill showing up to 12.2% loss in the same period. These data, coupled with an encouraging safety profile, reinforced hopes that Viking can become a serious contender in the fast‑growing obesity treatment market, which management views as a multibillion‑dollar opportunity.

Momentum is also being driven by rapid progress in late‑stage development. The Phase III VANQUISH program for injectable VK2735 is scaling quickly, with the obesity‑focused VANQUISH‑1 study already fully enrolled ahead of schedule and the diabetes‑related VANQUISH‑2 study close to completion. Viking is preparing to launch a Phase III program for the oral version of VK2735 in 2026, supported by a broad manufacturing deal with CordenPharma and the hiring of a seasoned chief commercial officer to build out launch infrastructure. Analysts at Jefferies, Truist, Maxim Group, and Piper Sandler have reiterated Buy ratings and set aggressive price targets, adding to the bullish sentiment.

At the same time, the rally comes despite mounting financial pressure and clear risks. Viking’s R&D spending has surged as it moves deeper into costly late‑stage trials, pushing quarterly and full‑year net losses sharply higher and driving a sizable cash burn, even though the company still holds a sizable $706 million cash cushion. Insider selling and a negative insider‑sentiment reading, along with rising competition in obesity drugs and uncertainty around future reimbursement, underline the execution challenges ahead. For now, however, investors appear focused on the impressive clinical results and expanding pipeline, betting that Viking Therapeutics’ heavy spending today could translate into significant long‑term value if its obesity franchise succeeds.